Market News / Story
Sionna Therapeutics, Inc. (SION) Plans Phase 2a For SION-451 + SION-2222 After Post Hoc Analyses
·
Sionna reported post hoc PreciSION CF analyses and new preclinical data, and said it plans to start AscenSION CF, a 28‑day Phase 2a of SION‑451 + SION‑2222 in F508del homozygous adults, in Q1 2027. Material Details #DetailAI Analyst View1Phase 2a planned to start Q1 2027Sets timeline for next clinical catalyst; start/initial readouts can move the stock.2Combo: SION-451 + SION-2222Signals pivot to a two-drug regimen aiming to avoid prior 4-drug interactions.3PreciSION…